Kintara Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

TuHURA Biosciences

23/09/2022 13:46

* Kintara Therapeutics Inc  KTRA.OQ   KTRA.O  is expected
to show
no change in quarterly revenue when it reports  results on
September 27 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Kintara
Therapeutics Inc
is for a loss of 3 cents per share. 
    * The one available analyst rating on the shares is
"hold".  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kintara
Therapeutics Inc is $3​, above​ its last closing price of $0.14.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.15       -0.15      -0.11     Beat    26.7
 Dec. 31 2022  -0.17       -0.16      -0.12     Beat    25
 Sep. 30 2021  -0.15       -0.14      -0.17     Missed  -17.2​
 Jun. 30 2021  -0.14       -0.16      -0.13     Beat    18.8
 ​​Mar.        -0.20       -0.18      -0.23     Missed  -26
 31 2021                                                
 Dec. 31 2020  -0.14       -0.14      -0.22     Missed  -54.4​
 Sep. 30 2020  -0.09       -0.09      -0.20     Missed  -122.2
 Jun. 30 2020  -0.09       -0.12      -0.33     Missed  -182.8
 This summary was machine generated September 23 at 12:46 GMT. 
All figures in US dollars  unless otherwise stated